Skip to content

Public FDA record

Z-0937-2021: therascreen PIK3CA RGQ PCR Kit (23) US IVD product- aid clinicians in identifying breast cancer patients

Recall record Z-0937-2021 for Qiagen Sciences LLC. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0937-2021
Company in FDA record
Qiagen Sciences LLC
FDA record creation date
Jan 29, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Kit may generate false Q546R mutation positive results caused by nonspecific molecular interactions within the Q546R higher than previously observed and described within the Instructions For Use.

Source facts

Action
Qiagen US notified customers by Urgent Medical Device Correction letter via e-mail on 12/11/20. The e-mail additionally contains the letter as PDF. Letter states reason for recall, health risk and action to take: For patient samples where a PIK3CA Mutation Detected Result is obtained, disregard Q546R positive results. Cease to report patient samples where a Q546R mutation result is obtained as PIK3CA Mutation Detected. Information about individual target results is specifically obtained from the Individual target result column of the Rotor-Gene Assay Manager v2.1 result table. If multiple mutations including Q546R are detected, disregard the Q546R result only. Continue to consider all other results as valid and report them accordingly. l For the purpose of run validity, Q546R control data must still be produced. The therascreen PIK3CA RGQ PCR Kit software requires valid run control data from the Q546R reaction for the overall test to be valid. Therefore, continue to use all supplied reagents and perform testing as described in the kit handbook, but disregard Q546R positive results generated for patient samples as described in the previous bullet points. l Forward this information to all individuals and departments within your organization who are using the therascreen PIK3CA RGQ PCR Kit REF 873121. If you are not the end-user, please forward this notice to the product end-user. l Review this notice with your laboratory/medical director. l Complete the Acknowledgement or Receipt Form attached to this letter by December 22, 2020 and email it to quality.communications@qiagen.com. QIAGEN is now revising the Instructions for Use for the therascreen PIK3CA RGQ PCR Kit, as described in this notice, to reduce any risk resulting from non-specific molecular interactions within the Q546R reaction leading to the generation of Q546R false mutation positive results. QIAGEN is also updating the therascreen PIK3CA FFPE and Plasma Assay Profile software packages to
Initiated
2020-12-11
Root cause
Process control
Terminated
2022-04-22
Distribution
CA, IN, MI, MN, NC, NJ, NM, OH, TX
Recall number
Z-0937-2021
Recall status
Terminated
CDRH record ID
185128
FDA record created
2021-01-29
Recall event number
87047

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗